

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7690913

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
KEDALION THERAPEUTICS, INC.	11/15/2022

**RECEIVING PARTY DATA**

<b>Name:</b>	NOVARTIS AG
<b>Street Address:</b>	LICHTSTRASSE 35
<b>City:</b>	BASEL
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	4056

**PROPERTY NUMBERS Total: 49**

Property Type	Number
Application Number:	17069404
Application Number:	62656552
Application Number:	16444894
Application Number:	16444897
Application Number:	16444904
Application Number:	16444912
Application Number:	16852123
Application Number:	62125073
Application Number:	14992975
Application Number:	16805188
Application Number:	62178464
Application Number:	15094849
Application Number:	17147196
Application Number:	62448791
Application Number:	15874377
Application Number:	62492624
Application Number:	62520270
Application Number:	62523071
Application Number:	62534083
Application Number:	17670215

PATENT

Property Type	Number
Application Number:	16463137
Application Number:	62596668
Application Number:	62613908
Application Number:	16972085
Application Number:	62693818
Application Number:	62653446
Application Number:	62814773
Application Number:	16811879
Application Number:	62814764
Application Number:	62913498
Application Number:	62934225
Application Number:	17096348
Application Number:	63317381
Application Number:	63321028
Application Number:	62951903
Application Number:	17127584
Application Number:	63049582
Application Number:	63011800
Application Number:	63049110
Application Number:	17509383
Application Number:	17692991
Application Number:	63011808
Application Number:	17233105
Application Number:	63166754
Application Number:	17233135
Application Number:	63159830
Application Number:	63212545
Application Number:	63323859
Application Number:	63337372

**CORRESPONDENCE DATA**

**Fax Number:** (617)310-6001

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 6173106000

**Email:** bosipmail@gtlaw.com

**Correspondent Name:** CHINH H. PHAM

**Address Line 1:** C/O GREENBERG TRAUIG, LLP

**Address Line 2:** ONE INTERNATIONAL PLACE, SUITE 2000

**Address Line 4:** BOSTON, MASSACHUSETTS 02110

<b>NAME OF SUBMITTER:</b>	CHINH H. PHAM
<b>SIGNATURE:</b>	/Chinh H. Pham, Reg. No. 39,329/
<b>DATE SIGNED:</b>	12/13/2022
<b>Total Attachments: 9</b> source=Executed_Assignment_Kedalion_Novartis#page1.tif source=Executed_Assignment_Kedalion_Novartis#page2.tif source=Executed_Assignment_Kedalion_Novartis#page3.tif source=Executed_Assignment_Kedalion_Novartis#page4.tif source=Executed_Assignment_Kedalion_Novartis#page5.tif source=Executed_Assignment_Kedalion_Novartis#page6.tif source=Executed_Assignment_Kedalion_Novartis#page7.tif source=Executed_Assignment_Kedalion_Novartis#page8.tif source=Executed_Assignment_Kedalion_Novartis#page9.tif	

## ASSIGNMENT

This Assignment Agreement is entered into by and between **KEDALION THERAPEUTICS, INC.**, whose address is One Health Plaza, East Hanover, New Jersey 07936, United States of America; a company organized under the laws of Delaware; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **KEDALION THERAPEUTICS, INC.** confirms that **KEDALION THERAPEUTICS, INC.** has sold, assigned, and transferred, and does hereby sell, assign, and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) listed on the attached APPENDIX A.

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **KEDALION THERAPEUTICS, INC.**, if this sale, assignment and transfer had not been made.

**KEDALION THERAPEUTICS, INC.**, hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

**KEDALION THERAPEUTICS, INC.**, hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation, or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the laws of Switzerland.


This Assignment is effective as from the earliest priority date as stated above.

Executed this 15th day of November, 2022 .

**KEDALION THERAPEUTICS, INC.**

BY   
\_\_\_\_\_  
Printed Name: Eduard Marti  
Authorized Signatory

Witness:   
\_\_\_\_\_  
Printed Name: Kristina Digravina  
City, State and Country: East Hanover, NJ, USA


Witness:   
\_\_\_\_\_  
Printed Name: Jenny Lo  
City, State and Country: East Hanover, NJ, USA

Executed this 1st day of December, 2022.


**NOVARTIS AG**


BY   
Printed Name: Hong-Van M. Le  
Authorized Signatory


Witness:   
Printed Name: Susan Dillon  
City, State and Country: Cambridge, MA, USA

Witness:   
Printed Name: Kathleen Drury  
City, State and Country: Cambridge, MA, USA

**NOVARTIS AG**

BY   
Printed Name: Xinsong (Nick) Xu  
Authorized Signatory

Witness:   
Printed Name: Susan Dillon  
City, State and Country: Cambridge, MA, USA

Witness:   
Printed Name: Kathleen Drury  
City, State and Country: Cambridge, MA, USA




**APPENDIX A**


<u>Novartis Reference</u>	<u>Kedalion Reference</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
PAT059388-US-CIP05	KEDA-017	US	17/069404	10/13/2020		
PAT059388-US-PSP	KEDA-010	US	62/656552	04/12/2018		
PAT059388-US-CIP	KEDA-010CIP	US	16/444894	06/18/2019		
PAT059388-US-CIP02	KEDA-010CIP2	US	16/444897	06/18/2019		
PAT059388-US-CIP03	KEDA-010CIP2	US	16/444904	06/18/2019		
PAT059388-US-CIP04	KEDA-010CIP3	US	16/444912	06/18/2019		
PAT059391-US-CNT	KEDA-001	US	16/852123	04/17/2020		
PAT059391-US-PSP	KEDA-001	US	62/125073	01/12/2015		
PAT059391-US-NP	KEDA-001	US	14/992975	01/11/2016	10624781	04/21/2020
PAT059392-US-CNT	KEDA-002/CON	US	16/805188	02/28/2020		
PAT059392-US-PSP	KEDA-002	US	62/178464	04/10/2015		
PAT059392-US-NP	KEDA-002	US	15/094849	04/08/2016	10583038	03/10/2020

<u>Novartis Reference</u>	<u>Kedalion Reference</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
PAT059393- US-CNT	KEDA-003	US	17/147196	01/12/2021		
PAT059393- US-PSP	KEDA-003	US	62/448791	01/20/2017		
PAT059393- US-NP	KEDA-003	US	15/874377	01/18/2018	10888454	01/12/2021
PAT059394- US-PSP	KEDA-004	US	62/492624	05/01/2017		
PAT059397- US-PSP	KEDA-005	US	62/520270	06/15/2017		
PAT059398- US-PSP	KEDA-006	US	62/523071	06/21/2017		
PAT059400- US-PSP	KEDA-007	US	62/534083	07/18/2017		
PAT059389- US-CNT	KEDA-008	US	17/670215	02/11/2022		
PAT059389- US-PCT	KEDA-008	US	16/463137	05/22/2019	11278448	03/22/2022
PAT059389- US-PSP	KEDA-008	US	62/596668	12/08/2017		
PAT059390- US-PSP	KEDA-009	US	62/613908	01/05/2018		

<u>Novartis Reference</u>	<u>Kedalion Reference</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
[REDACTED]						
PAT059395-US-PCT	KEDA-011	US	16/972085	12/04/2020		
PAT059395-US-PSP	KEDA-011	US	62/693818	07/03/2018		
PAT059396-US-PSP	KEDA-012	US	62/653446	04/05/2018		



PAT059399-US-PSP	KEDA-014	US	62/814773	03/06/2019		
PAT059399-US-NP	KEDA-014	US	16/811879	03/06/2020		
PAT059401-US-PSP	KEDA-015	US	62/814764	03/06/2019		
PAT059403-US-PSP	KEDA-017	US	62/913498	10/10/2019		
PAT059404-US-PSP	KEDA-018	US	62/934225	11/12/2019		
PAT059404-US-NP	KEDA-018	US	17/096348	11/12/2020		
PAT059413-US-PSP		US	63/317381	03/07/2022		
PAT059413-US-PSP02		US	63/321028	03/17/2022		



<u>Novartis Reference</u>	<u>Kedalion Reference</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
PAT059402-US-PSP	KEDA-019	US	62/951903	12/20/2019		
PAT059402-US-NP	KEDA-019	US	17/127584	12/18/2020		
PAT059402-US-PSP02	KEDA-019	US	63/049582	07/08/2020		
PAT059405-US-PSP	KEDA-020	US	63/011800	04/17/2020		
PAT059405-US-PSP02	KEDA-020	US	63/049110	07/07/2020		
PAT059406-US-CIP	KEDA-021	US	17/509383	10/25/2021		
PAT059406-US-CIP02	KEDA-021	US	17/692991	03/11/2022		
PAT059406-US-PSP	KEDA-021	US	63/011808	04/17/2020		
PAT059406-US-NP	KEDA-021	US	17/233105	04/16/2021		
PAT059407-US-PSP		US	63/166754	03/26/2021		
PAT059407-US-NP	KEDA-021	US	17/233135	04/16/2021		
PAT059408-US-PSP	KEDA-022	US	63/159830	03/11/2021		
PAT059409-US-PSP	KEDA-023	US	63/212545	06/18/2021		
PAT059410-US-PSP	KEDA-024	US	63/323859	03/25/2022		
PAT059411-US-PSP	KEDA-025	US	63/337372	05/02/2022		